(-)-P7C3-S243
(-)-P7C3-S243 is an orally active, blood-brain barrier permeable neuroprotective agent. (-)-P7C3-S243 binds to μ-opioid Receptor and TSPO. (-)-P7C3-S243 inhibits the premature apoptosis death of newborn hippocampal neurons, protects mature nigral dopaminergic neurons, promotes neuronal survival and prevents cognitive impairment. (-)-P7C3-S243 ameliorates depression-like behaviors in rat models. (-)-P7C3-S243 is applicable to research related to Parkinson's disease and Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 1597443-57-6
- Formula: C21H18Br2FN3O
- Molecular Weight:507.19
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Opioid Receptor Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCC44 | IC50 |
10 μM
Compound: (-)-(S)-15, (-)-P7C3-S243
|
Cytotoxicity against human HCC44 cells
Cytotoxicity against human HCC44 cells
|
[PMID: 24697290] |
In Vitro
(-)-P7C3-S243 (Compound 15) weakly inhibits CYP1A2 (IC50 = 20 μM) and CYP2C19 (IC50 = 1.9 μM) in vitro, but shows no inhibitory effect on multiple other tested CYP subtypes[1].
(-)-P7C3-S243 binds to the μ-opioid receptor (IC50 = 8.2 μM) and TSPO (IC50 = 0.35 μM) in vitro, but does not bind to most other tested neuronal receptors and channels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
(-)-P7C3-S243 (1-10 mg/kg; i.p.; twice daily for 21 consecutive days) dose-dependently protects mature dopaminergic neurons in the substantia nigra of mice treated with MPTP (HY-15608)[1].
(-)-P7C3-S243 (10 mg/kg; i.p.; 10 days) doubles the level of postnatal hippocampal neurogenesis in TgF344-AD rats, protects the rats from early depression-like behaviors and late cognitive impairment, reduces neurodegeneration and neuronal loss, and also ameliorates age-related depression-like behaviors in wild-type rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/J6 (12-week-old)[1]
-
Dosage:10 μM; 0.1-10 mg/kg/day
-
Administration:i.c.v.; 0.5 μL/h; 7 days; i.p.; BID; 7 days
-
Result:Approximately doubled the number of surviving BrdU+ newborn hippocampal neurons compared to vehicle-treated mice.
Showed a smooth dose-response curve, with activity detectable at 1 mg/kg/day and maximum efficacy achieved at 10 mg/kg/day; efficacy reflected increased survival of newborn hippocampal neurons via neuroprotection (not increased proliferation).
-
Animal Model:C57Bl/6 (adult male; MPTP-induced Parkinson's disease)[1]
-
Dosage:1, 3, 5, 10 mg/kg/day
-
Administration:i.p.; BID; 21 days
-
Result:Showed significant neuroprotective activity at 1 mg/kg/day, and at the highest tested dose of 10 mg/kg/day, rescued over 85% of TH+ dopaminergic neurons in the substantia nigra (compared to MPTP-treated vehicle controls).; Demonstrated higher efficacy than that of P7C3-A20, with strict enantiomeric specificity (only the (−)-S enantiomer was active).
-
Animal Model:Fischer 344 rats (male and female, 6 months old at treatment initiation; TgF344-AD transgenic overexpressing human mutant APP_SW and PS1ΔE9 genes; wild-type)[2]
-
Dosage:10 mg/kg/d
-
Administration:daily; 9 months (15-month assessments); 18 months (24-month assessments)
-
Result:Reduced time spent immobile in the Porsolt forced swim test in TgF344-AD rats to levels comparable to WT animals at 15 months.
Did not affect locomotor activity or cause cognitive deficits in any group at 15 months.
Improved performance in the Morris water maze reversal memory probe in TgF344-AD rats, reducing time to locate the target position to levels similar to WT animals at 24 months.
Ameliorated depression-like behavior in 24-month-old WT rats, reducing time spent immobile in the Porsolt forced swim test from mean 45 seconds to mean 20 seconds (p=0.0176), but did not correct depression-like behavior in 24-month-old TgF344-AD rats.
Significantly reduced vacuole formation in the hippocampus and cerebral cortex of TgF344-AD rats at 24 months.
Prevented neuronal cell loss in the hippocampus and cerebral cortex, and increased neuronal cell counts in the dentate gyrus granule cell layer of TgF344-AD rats at 24 months.
Did not alter amyloid plaque deposition, levels of soluble or insoluble Aβ1-40/Aβ1-42 peptides, tau hyperphosphorylation (Tau PS199/202), or glial activation (GFAP+ astrocytes or Iba1+ microglia) in TgF344-AD rats at 24 months.
Chemical Information
-
CAS No. 1597443-57-6
-
Molecular Weight 507.19
-
Formula C21H18Br2FN3O
-
SMILES
F[C@@H](CNC1=NC(OC)=CC=C1)CN2C3=CC=C(Br)C=C3C4=C2C=CC(Br)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Primary Embryonic Hippocampal Neuron Culture
Primary embryonic hippocampal neuron culture is an in vitro method in which hippocampi from embryonic rodents are dissected, enzymatically or mechanically dissociated, plated on adhesive substrates, and maintained in defined neuronal medium or in low-density sandwich/co-culture formats to support neuronal attachment, neurite extension, polarity formation, dendritic arborization, and synapse formation. The main readouts are cell survival, neuronal purity, neurite outgrowth, axon-dendrite polarization, synaptic marker development, and functional neuronal activity, assessed by phase-contrast microscopy, immunocytochemistry for neuronal/glial markers, live imaging, or electrophysiology depending on the downstream experiment.
-
Serum-Free B27/Neurobasal Neuronal Maintenance Culture
Serum-free B27/Neurobasal culture is a defined neuronal maintenance method designed to support dissociated primary neurons while limiting serum-driven glial expansion; the readout is sustained neuronal survival, neurite extension, neuronal marker expression, synapse formation, and, when measured, electrophysiological or calcium activity. B27/Neurobasal was optimized in embryonic rat hippocampal neurons, where B27 supported >60% survival after 4 days above 160 plated cells/mm2 and Neurobasal reduced glial growth to <0. 5% by immunocytochemistry; later studies extended the approach to cortex, striatum, substantia nigra, septum, cerebellum, and dentate gyrus neurons.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
[1]. Naidoo J, et al. Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties. J Med Chem. 2014;57(9):3746-3754. [Content Brief]
[2]. Voorhees JR, et al. (-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia. Biol Psychiatry. 2018;84(7):488-498. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)